Dose Escalation Study With Cabazitaxel in Combination With Daily Prednisolone in Patients With Hormone Refractory Prostate Cancer
Condition:   Prostate CancerInterventions:   Drug: Cabazitaxel (XRP6258);   Drug: prednisoloneSponsor:   SanofiActive, not recruiting - verified October 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 28, 2011 Category: Research Source Type: clinical trials

Blood for Immune Response to Provenge® in HRPC
Condition:   Prostate CancerIntervention:   Sponsor:   Mary Crowley Medical Research CenterWithdrawn - verified April 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 10, 2011 Category: Research Source Type: clinical trials

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Condition:   Prostate Cancer MetastaticIntervention:   Drug: CABAZITAXELSponsor:   SanofiActive, not recruiting - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 2, 2010 Category: Research Source Type: clinical trials

Early Access to Cabazitaxel in Patients With Metastatic Hormone Refractory Prostate Cancer Previously Treated With a Docetaxel-containing Regimen
Condition:   Prostate Cancer MetastaticIntervention:   Drug: CABAZITAXELSponsor:   SanofiCompleted - verified January 2015 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 2, 2010 Category: Research Source Type: clinical trials

Biomarkers of Response to Taxotere in HRPC. ICORG 08-08, V2
Conditions:   Metastatic Cancer;   Prostate CancerInterventions:   Drug: docetaxel;   Genetic: RNA analysis;   Genetic: reverse transcriptase-polymerase chain reaction;   Other: circulating tumor cell analysis;   Other: laboratory biomarker analysisSponsor:   ICORG- All Ireland Cooperative Oncology Research GroupRecruiting - verified August 2014 (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - July 9, 2010 Category: Research Source Type: clinical trials